Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 10/20 | 0.56 |
| ▸ | TOP1 | P11387 | 2/20 | 0.47 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.43 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5464092 | 0.86 | TOP1 (0.46) | SNCAALOX15TOP1P2RX1MEN1 | |
| SCHEMBL5469832 | 0.84 | LMNA (0.60) | SNCAP2RX1MAOBMEN1NPC1 | |
| SCHEMBL5463888 | 0.84 | PTGS1 (0.56) | P2RX1MAOAMEN1NPC1RAB9A | |
| SCHEMBL5462595 | 0.83 | SMN1; SMN2 (0.59) | P2RX1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL5463705 | 0.82 | SRC (0.55) | P2RX1MAOBMEN1NPC1RAB9A | |
| SCHEMBL5468424 | 0.80 | NPC1 (0.56) | TOP1MAOAMAOBADORA2BMEN1 | |
| SCHEMBL5462663 | 0.80 | MEN1 (0.47) | ALOX15TOP1P2RX1MAOAMAOB | |
| SCHEMBL5468828 | 0.79 | NPC1 (0.57) | ALOX15MEN1NPC1RAB9AKMT2A | |
| SCHEMBL5462330 | 0.79 | PNLIP (0.62) | ALOX15MEN1NPC1RAB9AKMT2A | |
| SCHEMBL5468746 | 0.79 | MEN1 (0.54) | MEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | claimed |
| EP-1666469-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2006-06-07 | — | — | EP | claimed |
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1666469-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | SNCA 4333/4885ALOX15 1536/4885TOP1 3819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.